The Wednesday biotech signal
Biologics capacity lands. Specialized work widens.
A completed manufacturing expansion, a late-stage licensing deal, pivotal-study preparation, and new research services all reward the teams that connect scientific programs to controlled execution.
JobReports original editorial image
768
Active biopharma jobs added
97
Biopharma employers
+33.1%
Versus last Wednesday
99
Clinical & medical roles
From market signal to personal shortlist
See which of today's roles fit your experience.
Create a free profile for personalized matches, or compare memberships for deeper AI scoring and application materials.
Manufacturing / Biologics capacity
Elanco completes a 25,000-square-foot Kansas expansion
Elanco says the new space at its Elwood manufacturing site is complete. The $120 million project increases upstream and downstream monoclonal-antibody capacity by more than four times and adds a pilot plant, quality-control laboratory, and support areas.
The operating site already makes two animal-health antibody products. Another $30 million is planned through 2028 for warehousing, which means the core manufacturing expansion is finished while the broader site investment continues.
Why it matters
Larger operating capacity raises the execution load across processing, quality control, validation, engineering, maintenance, materials, and production planning. Elanco says the project brings jobs to the region but did not provide a headcount or identify current vacancies.
Neurology / Global licensing
Biohaven shifts Kv7 execution to SK Biopharmaceuticals
Biohaven and SK Biopharmaceuticals announced an exclusive worldwide license for the Kv7 platform led by opakalim, now in Phase 2/3 development for focal epilepsy. The companies describe $400 million in scheduled cash consideration plus milestones, assumed obligations, and royalties.
SK will take on future program costs, focusing work on late-stage development, regulatory planning, alliance management, and commercialization. The transaction is subject to closing, the medicine remains investigational, and no hiring was announced.
Oncology / Phase 3 preparation
Vivace gets the green light to proceed with sTEADfast
Vivace says the FDA granted safe-to-proceed status for the pivotal sTEADfast study of VT3989 in mesothelioma after prior immunotherapy and chemotherapy. The company plans to begin the Phase 3 study later in 2026.
Clearance allows the study to move forward; it is not enrollment or approval. The next work surface includes site activation, safety, data, statistics, supply, regulatory, and vendor coordination. Vivace did not announce vacancies.
Gene therapy / Manufacturing services
Genezen adds synthetic DNA to viral-vector workflows
Genezen will offer 4basebio's cell-free synthetic DNA across research-use, development, and GMP-grade viral-vector services. The companies describe a non-exclusive collaboration spanning programs from early development toward clinical and commercial manufacturing.
The integration adds work in process development, analytical testing, supplier qualification, quality agreements, tech transfer, and GMP documentation. Performance claims are company-reported; neither partner disclosed added capacity or hiring.
Discovery tools / Platform licensing
Monod proteins move into custom research services
Monod Bio licensed its LuxSit luciferase and NovoBodies binding proteins to SignalChem Biotech. SignalChem may use the designed proteins in custom luminescent-assay development and protein-fusion services for research customers.
Turning a protein-design platform into customer services points toward assay development, validation, technical support, and scientific product work. The non-exclusive agreement includes no disclosed financial terms, revenue forecast, or hiring plan.
Wednesday volume expands
JobReports added 768 active biotechnology and pharmaceutical opportunities from 97 employers between midnight Eastern and today's cutoff. That is about 33.1% above the comparable Wednesday window one week earlier. Clinical and medical work led the named role families, followed by commercial and business roles.
These are active opportunities first captured by JobReports before cutoff, not employer-supplied posting times. Role-family and location classifications are directional.
76
U.S.-remote roles
24
Boston roles
20
North Chicago roles
Editor's shortlist
Five roles worth a closer look
Senior Director, Head of Clinical Pharmacology
San Francisco, California
Associate Director, Global Regulatory Affairs Compliance
Boston, Massachusetts
Principal Engineer, Lentivirus Downstream Process Development
Somerset, New Jersey
Aseptic Manufacturing Technician I — Day Shift A
Philadelphia, Pennsylvania · Contract to hire
Staff AI Researcher
Remote, United States
The takeaway
Scientific programs still need people who can make them run.
A larger biologics site, a transferred late-stage program, a pivotal-study green light, and new research-service combinations all point to disciplined execution. Today's verified roles carry that pattern into clinical pharmacology, regulatory compliance, vector processing, aseptic manufacturing, and AI research.